‌

US Patent 10702508 Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Patent 10702508 was granted and assigned to Aragon Pharmaceuticals on July, 2020 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Patent Applicant

Aragon Pharmaceuticals

Current Assignee

Aragon Pharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

107025080

Date of Patent

July 7, 2020

Patent Application Number

159674520

Date Filed

April 30, 2018

Patent Citations

‌

US Patent 10052314 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Patent Citations Received

‌

US Patent RE49353 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

‌

US Patent 11491149 Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Patent Primary Examiner

‌

Kevin E. Weddington

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10702508 Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API